Abstract:
Mucormycosis is a fatal fungal infection which emerges as a serious complication of
COVID-19. It increased significantly in prevalence in the last few years especially in
immunocompromised patients. Clinically, it has different types, pulmonary
mucormycosis, Gastrointestinal tract mucormycosis, renal mucormycosis, Cutaneous
mucormycosis, disseminated mucormycosis, but the most common type to develop is
Rhino-orbital-cerebral-mucormycosis (ROCM).
A fast definitive diagnosis is the most critical step to determine the type of treatment
with either a surgical or pharmacological approach and to confine the spread of the
infection to neighboring tissues to achieve a better prognosis with reconstruction of
affected area and decrease the rate of mortalities.
The aim of this review is to discuss mucormycosis based on evidence from 1957 until
2022 taken from different countries, to shine light on causative factor, clinical
presentation, radiographic appearance, its classifications and treatment using
surgical and pharmacological pathways, also show the recent reconstruction methods
performed, as well as its mortality rate.
